14504-07-5

Basic information

• Product Name: 2-Acetyl-4-methylsalicylicacid
• Synonyms: 2-Acetoxy-4-methylbenzoicacid;2-Acetyl-4-methylsalicylicacid;O-ACETYL-4-METHYLSALICYLIC ACID;Benzoic acid, 2-(acetyloxy)-4-Methyl-;2-(Acetyloxy)-4-methylbenzoic acid
• CAS NO: 14504-07-5
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.184
• Mol File: 14504-07-5.mol

Chemical Properties

• Appearance: /
• Density: 1.245
• CAS DataBase Reference: 2-Acetyl-4-methylsalicylicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Acetyl-4-methylsalicylicacid(14504-07-5)
• EPA Substance Registry System: 2-Acetyl-4-methylsalicylicacid(14504-07-5)

Safety Data

• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36:Wear suitable prot
• Hazardous Substances Data: 14504-07-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Acetyl-4-methylsalicylic acid is used as an intermediate in the synthesis of other organic compounds and in the production of pharmaceuticals for its versatile properties.
Used in Pain Management:
2-Acetyl-4-methylsalicylic acid is used as an analgesic agent for the treatment of pain due to its ability to alleviate discomfort and reduce inflammation.
Used in Fever Reduction:
2-Acetyl-4-methylsalicylic acid is used as an antipyretic agent to reduce fever by lowering body temperature and providing relief from associated symptoms.
Used in Inflammation Treatment:
2-Acetyl-4-methylsalicylic acid is used to treat inflammation, helping to decrease swelling and redness associated with various conditions.

Upstream product

• 50-85-1 2-hydroxy-p-toluic acid 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 

Downstream Products

• 57148-35-3 2-acetoxy-4-methyl-benzoyl chloride 
• 13515-12-3 methyl 2-acetoxy-4-methylbenzoate 
• 1237519-25-3 methyl 2-(2-acetoxy-4-methylbenzamido)-4-phenylbenzoate 
• 1237514-75-8 2-(2-hydroxy-4-methylbenzamido)-4-phenylbenzoic acid 
• 1590343-09-1 4-amino-2-imino-8-methyl-1,2-dihydro-5H-chromeno[2,3-d]pyrimidin-5-one 
• 1375074-75-1 4-imino-8-methyl-3-phenyl-2-thioxo-1,2,3,4-tetrahydro-5H-chromeno[2,3-d]pyrimidine-5-one 
• 99601-62-4 C₂₂H₃₆NO₃P 
• 49667-22-3 2-hydroxy-4-methylbenzamide 

Relevant articles and documents

Development of methylated cobalt–alkyne complexes with selective cytotoxicity against COX-positive cancer cell lines

Derivatives of the cytotoxic cyclooxygenase (COX) inhibitor [(prop-2-ynyl)?2-acetoxybenzoate]dicobalthexacarbonyl (Co-ASS) with a methyl group in the 3, 4, 5, or 6 position of the acetylsalicylic acid (ASS) scaffold were synthesized with the aim to achieve enhanced selectivity for COX-2. From this modification, a higher specificity for COX-2-expressing tumors is expected, preventing COX-1-mediated side effects. The cobalt–alkyne complexes were tested for their COX-inhibitory and antiproliferative properties as well as their cellular uptake. Methylation reduced the effects at the isolated COX-1, whereas those at the isolated COX-2 remained nearly constant compared to Co-ASS. In cellular systems, the new compounds showed superior cytotoxicity toward the COX-positive HT-29 colon carcinoma cells than cisplatin. The reduced growth-inhibitory potency in T-24 cells, which express distinctly fewer COX enzymes (COX-1/COX-2 = 50/1) than HT-29 cells (COX-1/COX-2 = 50/50), and the only marginal activity in COX-negative MCF-7 breast cancer cells point to an interference in the arachidonic acid cascade through COX-2 inhibition as part of the mode of action, especially as the cellular uptake was even higher in MCF-7 cells than in T-24 cells. These findings clearly demonstrate that the methylated cobalt–alkyne complexes possess promising potential for further development as reasonable alternatives to the limited platinum-based antitumor agents.

Synthesis and antioxidant activities of berberine 9-: O -benzoic acid derivatives

Although berberine (BBR) shows antioxidant activity, its activity is limited. We synthesized 9-O-benzoic acid berberine derivatives, and their antioxidant activities were screened via ABTS, DPPH, HOSC and FRAP assays. The para-position was modified with halogen elements on the benzoic acid ring, which led to an enhanced antioxidant activity and the substituent on the ortho-position was found to be better than the meta-position. Compounds 8p, 8c, 8d, 8i, 8j, 8l, and especially 8p showed significantly higher antioxidant activities, which could be attributed to the electronic donating groups. All the berberine derivatives possessed proper lipophilicities. In conclusion, compound 8p is a promising antioxidant candidate with remarkable elevated antioxidant activity and moderate lipophilicity.

COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES

The present invention refers to compounds of formula: (formula A), wherein R1 is selected from (formula I), (formula II), (formula (III), (formula IV), (formula V), or (formula B), and wherein R2, R3, R4 and Rs

Derivatives of 1,4-bis(3-hydroxycarbonyl-4-hydroxyl)styrylbenzene as PTP1B inhibitors with hypoglycemic activity

Disalicylic acid derivatives with stilbene and bis-styrylbenzene skeleton were synthesized as PTP1B inhibitors. The most potent in this series exhibited a submicromolar IC50 value. One of the compounds 7b was tested in an animal model for its efficacy as an anti-diabetic or an anti-obesity agent. In feeding compound 7b to diet-induced obese mice, no significant differences in weight gain and food consumption were observed between the drug-treated and the obese control mice. However, 7b significantly lowered the fasting glucose level and improved the glucose tolerance in the obesity-induced diabetic mice.

4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described.

A Novel Synthesis of 4H-Chromen-4-ones via Intramolecular Wittig Reaction

formula presented The acylphosphoranes formed in a sequential manner from the reaction of the silyl ester of O-acyl(aroyl)salicylic acids and (trimethylsilyl)-methylenetriphenylphosphorane undergo intramolecular Wittig cyclization on the ester carbonyl to afford the 4H-chromen-4-ones in good to excellent yields.

Novel quinolizidine salicylamide influenza fusion inhibitors

A novel series of quinolizidine salicylamides was synthesized as specific inhibitors of the H1 subtype of influenza A viruses. These inhibitors inhibit the pH-induced fusion process, thereby blocking viral entry into host cells. Compound 16 was the most active inhibitor in this series with an EC50 of 0.25 μg/mL in plaque reduction assay. The synthesis and the SAR of these compounds are discussed.

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers

A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2-induced and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for oral hypotensive effects in spontaneously hypertensive rats. An electron- withdrawing group with the proper shape at C6 and a methyl or halogens group at C7 of the 1,3-benzoxazine nucleus were required for the development of optimal vasorelaxant and hypotensive activity. In particular, 2-(6-bromo-7- chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine 1-oxide (71) showed more potent vasorelaxant activity (EC50=0.14 μM) against TEA and BaCL2- induced contraction and longer-lasting hypotensive effects than cromakalim (1).